Decision/Conclude agreement
Proposed
方達控股目標業務出售予Charles River Laboratories
Tigermed's privatization of Frontage Holdings splits its business, with the bioanalytical and DMPK target business to be sold to Charles River Laboratories at a preliminary valuation of about US$470 million.
Trajectories
Sign-in readers can mine up to three arcs for this record.
Actors and targets
Source
生物分析及藥物代謝動力學(DMPK)等目標業務將出售予Charles River Laboratories,初步估值約4.7億美元
Extracted detail
- Bank
- 瑞銀
- Currency
- USD
Related decisions
Same kind only, ranked by embedding similarity to this record.